SAINT PAUL, Minn., Aug. 6, 2012 /PRNewswire/ -- Enterologics, Inc (ELGO) reported today that as the scientific literature regarding probiotics continues to expand, so does information on the web continue to proliferate. Some of the websites provide excellent, balanced information, others provide healthy skepticism, and many others recycle general information or make over-hyped claims. The challenge is finding good sources of information for a consumer to guide selection among the many over-the-counter products that are now available.
Some useful sites include the following:
The Mayo Clinic website provides a source of balanced information about various health issues. A search for "probiotics" yields a wealth of useful information about what is known about probiotics, particularly for their potential role in various disease states.
The International Scientific Association for Probiotics and Prebiotics provides solid scientific information and updates on recent and forthcoming scientific conferences.
USProbiotics.org is a dairy industry-sponsored site. It is a collaboration between the California Dairy Research Federation and Dr. Mary Ellen Sanders, a frequent contributor to scientific journals on probiotics. The website provides multiple useful links to other sites regarding the science and emerging regulatory issues surrounding probiotic products.
Doses of healthy skepticism are provided at Science Based Medicine. This is a blog commentary on many controversial topics in medicines, particularly for therapies and procedures that the contributors think have been accepted to readily.
The Company indicated that from time to time, it will highlight additional sources of useful information regarding the emerging science related to probiotics, the normal gastrointestinal microflora, and health.
Enterologics, Inc (ELGO) is a biotechnology company that is developing probiotics as biologic drugs for specific gastrointestinal disease indications. Probiotics are live microorganisms, in most cases, bacteria, that are similar to or derived from beneficial microorganisms that are found in the human gut (e.g. for more information see Introduction to Probiotics). They are also called "friendly bacteria" or "good bacteria." Enterologics intends to develop unique probiotic strains for specific medical conditions, obtain regulatory approval and market these probiotics products as FDA-approved prescription drugs for specific label indications. The first probiotic product in its portfolio is E. coli M17, which is being developed for specific gastrointestinal indications.
For further information, contact email@example.com or visit www.enterologics.com.
Key Words: probiotics, biologics, biotechnology, gastrointestinal diseases
Matters discussed in this release may constitute forward-looking statements. The U.S. Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation.
Forward-looking statements reflect our current views with respect to future events and financial performance and may include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The words "believe," "intend," "anticipate," "estimate," "project," "promise," "plan," "potential," "may," "should," "expect" and similar expressions identify forward-looking statements.
The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, the consummation of the acquisition described above, the ability to obtain regulatory approval and market its products, availability of capital, management's examination of historical operating trends, data contained in our records and other data available from third parties. Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies which are difficult or impossible to predict and are beyond our control, we cannot assure you that it will achieve or accomplish these expectations, beliefs or projections.
Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include our ability to identify and in-license and the ability to adequately fund such targeted acquisitions. Risks and uncertainties are further described in reports filed by Enterologics, Inc with the U.S. Securities and Exchange Commission.
SOURCE Enterologics, Inc